A. Deol

M. Norkin, W. Wood, M. Aljurf, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML

J. Abrams, A. Deol, L. Lum, 2013, Bone Marrow Transplantation.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.

J. Abrams, A. Deol, J. Zonder, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

A. Deol, L. Lum, 2010, Cancer treatment reviews.

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

H. Kohrt, R. Vij, M. Aljurf, 2012, Blood.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, The Lancet.

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

J. Vose, D. Miklos, A. Rapoport, 2018, Blood.

Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review

J. Abrams, A. Deol, V. Ratanatharathorn, 2022, Journal of oncology.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Alan M. Miller, R. Vij, M. Aljurf, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

J. Vose, M. Kersten, C. Jacobson, 2021, Blood.

Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation

A. Deol, Seongho Kim, S. Revankar, 2018, Bone Marrow Transplantation.

Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.

A. Thakur, A. Deol, J. Zonder, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

S. Jagannath, A. Jakubowiak, N. Munshi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liver Graft‐Versus‐Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients

A. Deol, V. Ratanatharathorn, J. Uberti, 2019, American journal of hematology.

High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.

A. Deol, E. Waller, L. Lum, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

S. Forman, A. Deol, L. Lum, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.

A. Deol, L. Lum, V. Ratanatharathorn, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis

A. Deol, Seongho Kim, J. Uberti, 2021, Leukemia & lymphoma.

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

J. Vose, D. Miklos, A. Rapoport, 2019, Blood.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

I. Flinn, D. Miklos, C. Jacobson, 2019, The Lancet. Oncology.

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

J. Vose, D. Miklos, A. Rapoport, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

J. Vose, D. Miklos, A. Rapoport, 2019, Blood.

Grade 3–4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation

A. Deol, Seongho Kim, V. Ratanatharathorn, 2021, Leukemia & lymphoma.

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

P. Philip, A. Shields, A. Thakur, 2020, Oncoimmunology.

Post-transplant Cyclophosphamide versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for AML and MDS.

A. Deol, Seongho Kim, V. Ratanatharathorn, 2021, Transplantation and cellular therapy.

Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G‐CSF or G‐CSF and plerixafor mobilized grafts

Paramveer Singh, A. Deol, Seongho Kim, 2020, American journal of hematology.

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, Blood.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

A. Deol, Seongho Kim, L. Lum, 2015, Clinical lymphoma, myeloma & leukemia.

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

A. Deol, E. Waller, L. Lum, 2017, Bone Marrow Transplantation.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

I. Flinn, D. Miklos, C. Jacobson, 2021, Blood.

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

A. Thakur, A. Deol, L. Lum, 2014, Journal of Translational Medicine.

Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis

A. Deol, Seongho Kim, V. Ratanatharathorn, 2021, Annals of Hematology.

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT

A. Deol, L. Lum, V. Ratanatharathorn, 2015, Bone Marrow Transplantation.

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome

A. Deol, J. Uberti, V. Ratanatharathorn, 2017, Bone Marrow Transplantation.

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

M. Levis, M. Patnaik, A. Deol, 2020, Bone Marrow Transplantation.

Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium.

D. Miklos, A. Rapoport, M. Lunning, 2019, Journal of Clinical Oncology.

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

C. Jacobson, N. Jain, L. Akard, 2021, Blood.

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

D. Miklos, E. Jacobsen, C. Jacobson, 2018 .

Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

P. Pellett, A. Thakur, A. Deol, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

I. Flinn, D. Miklos, C. Jacobson, 2020 .

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

D. Miklos, C. Jacobson, N. Bartlett, 2020, Blood.

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.

J. Vose, D. Miklos, A. Rapoport, 2020, Blood.

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

J. Vose, D. Miklos, P. Jain, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

J. Vose, M. Kersten, C. Jacobson, 2021, British journal of haematology.

SAFETY AND EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN OLDER PATIENTS: RESULTS FROM THE US LYMPHOMA CAR‐T CONSORTIUM

J. Vose, D. Miklos, A. Rapoport, 2019, Hematological Oncology.

Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.

A. Deol, Vijendra Singh, Aditi Sharma, 2022, Transplantation and cellular therapy.

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

D. Miklos, E. Jacobsen, C. Jacobson, 2018 .

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium

Michael L. Wang, J. Vose, D. Miklos, 2021, Blood.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

J Wagner, F. Awan, M. Krem, 2022, Transplantation and cellular therapy.

Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma

A. Deol, Seongho Kim, V. Ratanatharathorn, 2020, Leukemia and Lymphoma.

G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD

A. Deol, Seongho Kim, V. Ratanatharathorn, 2020, Leukemia & lymphoma.

CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

A. Thakur, A. Deol, Qin Liu, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

W. Wood, H. Jim, J. Wingard, 2022, Transplantation and cellular therapy.

Malignant cause of abdominal pain in leukemia: spontaneous splenic rupture.

H. Mamdani, A. Deol, D. Modi, 2015, The American journal of the medical sciences.

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML

M. Patnaik, A. Deol, R. Maziarz, 2018, Blood.

R-BEAM versus Reduced Intensity Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.

A. Deol, Seongho Kim, V. Ratanatharathorn, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML)

M. Levis, M. Patnaik, A. Deol, 2019, Biology of Blood and Marrow Transplantation.

Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation

A. Deol, Seongho Kim, V. Ratanatharathorn, 2020, Bone Marrow Transplantation.

Encouraging Outcomes in African-American Patients with Use of Post-Transplant Cyclophosphamide after HLA Mismatched Hematopoietic Stem Cell Transplant

A. Deol, L. Lum, D. Aggen, 2015 .

Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant

A. Deol, L. Lum, V. Ratanatharathorn, 2014, Journal of clinical apheresis.

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.

J. Vose, F. Gao, D. Miklos, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma

A. Deol, J. Uberti, 2020, American journal of hematology.

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.

D. Porter, R. Richards, A. Deol, 2022, Future oncology.

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

I. Flinn, D. Miklos, C. Jacobson, 2018, Biology of Blood and Marrow Transplantation.

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation

A. Deol, Seongho Kim, L. Lum, 2016, American journal of hematology.

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Humoral Anti-Myeloma Immunity

A. Thakur, A. Deol, J. Zonder, 2013 .

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

F. Gao, C. Hofmeister, R. Vij, 2022, Leukemia.

Mortality in COVID-19 hospitalizations with underlying hematologic malignancies in the United States.

A. Deol, Vijendra Singh, Aditi Sharma, 2023, Hematological oncology.

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

W. Wood, H. Jim, J. Wingard, 2023, Transplantation and cellular therapy.

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

F. Gao, C. Hofmeister, R. Vij, 2019, Blood.

Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?

Nadine H Abdallah, A. Deol, Seongho Kim, 2018, Bone Marrow Transplantation.

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

D. Siegel, E. Ostertag, A. Deol, 2021, Blood.

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

M. Patnaik, A. Deol, R. Maziarz, 2016 .

A phase II study of tacrolimus and thymoglobulin as graft‐versus‐host‐disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

A. Deol, V. Ratanatharathorn, J. Uberti, 2018, American journal of hematology.

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

C. Hofmeister, R. Vij, J. Kaufman, 2018, Blood.

Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission

A. Deol, Seongho Kim, V. Ratanatharathorn, 2023, Leukemia & lymphoma.

A Retrospective Comparison of Outcomes in AML/MDS Patients Undergoing Allogeneic Stem Cell Transplant with Reduced Intensity and Myeloablative Conditioning Regimens

A. Deol, Seongho Kim, V. Ratanatharathorn, 2017 .

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, A. Lesokhin, 2023, Journal of Clinical Oncology.

Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation

A. Deol, Seongho Kim, S. Revankar, 2018, Bone Marrow Transplantation.

Impact of pre-transplant induction therapy on outcomes of patients who undergo autologous stem cell transplantation for mantle cell lymphoma in first complete remission.

A. Deol, Seongho Kim, V. Ratanatharathorn, 2020, Hematology/oncology and stem cell therapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

I. Flinn, D. Miklos, C. Jacobson, 2023, Blood.

J. Abrams, A. Deol, J. Zonder, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

J. Vose, L. Lekakis, M. Lunning, 2023, Blood advances.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

A. Deol, Seongho Kim, L. Lum, 2015, Clinical lymphoma, myeloma & leukemia.